TG Therapeutics reports positive Phase 1 results for subcutaneous BRIUMVI, advancing MS treatment options.

TG Therapeutics announced positive Phase 1 trial results for a new high-concentration subcutaneous formulation of BRIUMVI (ublituximab), showing good safety, tolerability, and effective drug exposure compared to the intravenous form. This subcutaneous version, designed for quarterly self-administration at home, could significantly reduce injection frequency for multiple sclerosis patients and expand the market. The ongoing Phase 3 trial is fully enrolled, with top-line data expected by late 2026 or early 2027, potentially leading to FDA approval in 2028. The results support the potential for a more convenient treatment option for relapsing multiple sclerosis, improving patient experience and access.